Comparison of Drug Switching and Discontinuation Rates in Patients with Nonvalvular Atrial Fibrillation Treated with Direct Oral Anticoagulants in the United States

Clinical events after interruption of anticoagulation in patients with atrial fibrillation: An analysis from the ENGAGE AF-TIMI 48 trial

(2018) Ilaria Cavallari et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Discontinuation risk comparison among ‘real-world’ newly anticoagulated atrial fibrillation patients: Apixaban, warfarin, dabigatran, or rivaroxaban

(2018) Gregory Y. H. Lip et al.   PLoS One

High number of newly initiated direct oral anticoagulant users switch to alternate anticoagulant therapy

(2017) Beenish S. Manzoor et al.   JOURNAL OF THROMBOSIS AND THROMBOLYSIS

Real-World Adherence and Persistence with Direct Oral Anticoagulants in Adults with Atrial Fibrillation

(2017) Beenish S. Manzoor et al.   PHARMACOTHERAPY

Real-World Setting Comparison of Nonvitamin-K Antagonist Oral Anticoagulants Versus Vitamin-K Antagonists for Stroke Prevention in Atrial Fibrillation

(2017) George Ntaios et al.   STROKE

Major bleeding risk and healthcare economic outcomes of non-valvular atrial fibrillation patients newly-initiated with oral anticoagulant therapy in the real-world setting

(2017) Jay Lin et al.   JOURNAL OF MEDICAL ECONOMICS

Direct Oral Anticoagulants for the Management of Thromboembolic Disorders

(2016) Alpesh Amin et al.   CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS

An early evaluation of bleeding-related hospital readmissions among hospitalized patients with nonvalvular atrial fibrillation treated with direct oral anticoagulants

(2016) Steve Deitelzweig et al.   CURRENT MEDICAL RESEARCH AND OPINION

Major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: a “real-world” observational study in the United States

(2016) Gregory Y. H. Lip et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin

(2016) Allison Keshishian et al.   THROMBOSIS AND HAEMOSTASIS

Outcomes of Temporary Interruption of Rivaroxaban Compared With Warfarin in Patients With Nonvalvular Atrial Fibrillation

(2014) Matthew W. Sherwood et al.   CIRCULATION

Estimates of Current and Future Incidence and Prevalence of Atrial Fibrillation in the U.S. Adult Population

(2013) Susan Colilla et al.   AMERICAN JOURNAL OF CARDIOLOGY

Atrial fibrillation: Profile and burden of an evolving epidemic in the 21st century

(2013) Jocasta Ball et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Outcomes of Discontinuing Rivaroxaban Compared With Warfarin in Patients With Nonvalvular Atrial Fibrillation

(2013) Manesh R. Patel et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Adherence to anticoagulant treatment with dabigatran in a real-world setting

(2013) S. Schulman et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Edoxaban versus Warfarin in Patients with Atrial Fibrillation

(2013) Robert P. Giugliano et al.   NEW ENGLAND JOURNAL OF MEDICINE

Estimation of Total Incremental Health Care Costs in Patients With Atrial Fibrillation in the United States

(2011) Michael H. Kim et al.  

Apixaban versus Warfarin in Patients with Atrial Fibrillation

(2011) Christopher B. Granger et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation

(2011) Manesh R. Patel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dabigatran versus Warfarin in Patients with Atrial Fibrillation

(2009) Stuart J. Connolly et al.   NEW ENGLAND JOURNAL OF MEDICINE